))
A Conversation with Travera
Manage episode 371302390 series 3237644
Контент предоставлен Down There Aware. Весь контент подкастов, включая эпизоды, графику и описания подкастов, загружается и предоставляется непосредственно компанией Down There Aware или ее партнером по платформе подкастов. Если вы считаете, что кто-то использует вашу работу, защищенную авторским правом, без вашего разрешения, вы можете выполнить процедуру, описанную здесь https://ru.player.fm/legal.
This week Mary and Alex speak with Cliff Reed, Founding CEO, and Dennis Watson, VP Business Development, of Travera, a company specializing in new technology enhancing the landscape of late stage cancer treatment.
Listen on our website, www.downthereaware.com/podcast, or wherever you get your podcasts.
#Podcast #Spotify #Anchor #research #advocacy #cancer #Travera #genomics #DNA #MIT #FDA #CLIA #LDT #cancerresearch #technology #cancertechnology #innovation #groundbreaking #latestagecancer #stage4cancer #uterinecancer #ovariancancer #leukemia
Stay Connected
Email Us: downthereaware@gmail.com
Instagram:@downthereaware
Facebook: Down There Aware
Twitter: @downthereaware
Pinterest: Down There Aware
TikTok: Down There Aware
Episode Links
Episode Highlights
Intro [0:13]
Welcome Back! [1:25]
Guest introductions [1:44]
M.I.T. technology [3:42]
Genomics and DNA sequencing [3:58]
Limited patients [4:05]
New measurement tool [4:48]
MIT/Dana Farber Cancer Institute partnership [5:32]
Infectious disease comparison [5:48]
Multiple Myeloma [6:38]
“Cheat code” [7:30]
Commercial launch [9:09]
Test offered for free [10:15]
Working with physicians [10:55]
Trial and error process for patient [13:20]
Advocacy groups [15:25]
Patient profile [16:01]
Cancer mutation [17:57]
Access to live cancer cells [18:38]
Quick turn-around for results[21:30]
No additional burden on patient [23:35]
Early stage testing and limited data [24:28]
Predictive accuracy over 80% [25:12]
Late stage cancer patients [26:25]
Response from oncology community [28:00]
Difference in this x vivo test [29:25}
No financial risk [30:00]
Great value to research and future patients [31:57]
MIT intent [34:57]
Great creative minds in scientific research [36:15]
Future of Travera’s efforts [36:55]
The bigger plan [39:01]
FDA approval/CLIA certification [40:05]
Laboratory Developed Test (LDT) [40:21]
Potential to greatly benefit newly diagnosed patients[41:49]
Microchip specs [43:45]
Physics vs biochemistry[46:20]
Simple comparison to a diving board [47:05]
Speed and logic [49:47]
If someone is listening today and is interested [51:30]
dwatson@travera.com [52:23]
PHI and HIPAA [53:35]
Hearing from those who know best [55:03]
Thanks for listening! [56:19]
Stay Connected
Podcast, Spotify, Anchor, research, advocacy, cancer, Travera, genomics, DNA, MIT, FDA, CLIA, LDT, cancer research, technology, cancer technology, innovation, groundbreaking, late-stage cancer, stage 4 cancer, uterine cancer, ovarian cancer, leukemia
127 эпизодов
Поделиться
